UTHR
United Therapeutics Corporation
October 8, 2026 · market open
- Rarity
- 1.23
- Peak move
- −3.59%
- Float cap
- $23.0B
United Therapeutics Corporation is a public benefit corporation that develops and commercializes therapies for people with serious diseases and unmet medical needs. It markets and sells treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. Its products are sold primarily in the United States, with some sales in select international markets.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
9 events · 2 from SEC or newswire · 0 timed with the move- Key event
analyst_ratingRBC raised its price target on United Therapeutics to $708 from $677 and kept an Outperform rating.
insider_saleChairperson & CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics on October 6, 2026 at prices from $527.90 to $545.50, leaving 324,443 shares held.
SEC4 0001106578-26-000158board_changeUnited Therapeutics appointed Victor Dzau, M.D., former president of the National Academy of Medicine and former CEO of Duke University Health System, to its Board of Directors.
- Key event
analyst_ratingMorgan Stanley analyst Terence Flynn raised the price target on United Therapeutics to $566 from $515 while keeping an Equal Weight rating, adjusting models ahead of Q3 earnings.
insider_saleUnited Therapeutics EVP Paul Mahon sold 8,300 shares at an average price of $564 on Thursday, October 1.
- Key event
litigation_outcomeThe US Court of Appeals for the Third Circuit affirmed dismissal of Sandoz's antitrust claims accusing United Therapeutics of obstructing a generic Remodulin competitor by acquiring all commercially available treprostinil pump cartridges, finding procompetitive justifications.
insider_saleChairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $117.76 and sold all 9,500 shares across 11 transactions on October 5, 2026 at weighted average prices of $536.26 to $546.63 under a pre-arranged 10b5-1 plan, per a Form 4 filed October 6, leaving 324,443 shares held.
class_action_filedSueWallSt notified investors of a pending investigation into potential securities law violations on behalf of Liquidia investors who lost money after the court ruling put Yutrepia's PH-ILD indication at risk, with Liquidia shares falling roughly 57%.
patent_eventA US District Court for the District of Delaware found that Liquidia Technologies infringes claims 1 and 14 of United Therapeutics' US Patent No. 11,826,327 covering inhaled treprostinil for PH-ILD through Yutrepia marketing, rejected Liquidia's invalidity challenges, and United Therapeutics seeks an FDA order withdrawing Yutrepia's approval.